IS8410A - Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma - Google Patents

Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma

Info

Publication number
IS8410A
IS8410A IS8410A IS8410A IS8410A IS 8410 A IS8410 A IS 8410A IS 8410 A IS8410 A IS 8410A IS 8410 A IS8410 A IS 8410A IS 8410 A IS8410 A IS 8410A
Authority
IS
Iceland
Prior art keywords
reagents
treatment
methods
inflammatory disorders
immune inflammatory
Prior art date
Application number
IS8410A
Other languages
English (en)
Inventor
Roydon Jost-Price Edward
B. Brasher Bradley
W. Chappell Todd
Manivasakam Palaniyandi
Sachs Noah
Smith Brendan
A. Auspitz Benjamin
S. Slavonic Michael
Original Assignee
Combinatorx, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx, Incorporated filed Critical Combinatorx, Incorporated
Publication of IS8410A publication Critical patent/IS8410A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS8410A 2003-09-15 2006-04-12 Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma IS8410A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50302603P 2003-09-15 2003-09-15
PCT/US2004/030210 WO2005027839A2 (en) 2003-09-15 2004-09-15 Methods and reagents for the treatment of immunoinflammatory disorders

Publications (1)

Publication Number Publication Date
IS8410A true IS8410A (is) 2006-04-12

Family

ID=34375301

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8410A IS8410A (is) 2003-09-15 2006-04-12 Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma

Country Status (18)

Country Link
US (1) US20050192261A1 (is)
EP (1) EP1670427A4 (is)
JP (1) JP2007516217A (is)
KR (1) KR20060089725A (is)
CN (1) CN101102760A (is)
AR (1) AR047841A1 (is)
AU (1) AU2004273880A1 (is)
BR (1) BRPI0414435A (is)
CA (1) CA2537989A1 (is)
IL (1) IL174185A0 (is)
IS (1) IS8410A (is)
MX (1) MXPA06002929A (is)
NO (1) NO20061239L (is)
RU (1) RU2006112587A (is)
SG (1) SG146653A1 (is)
TW (1) TW200522932A (is)
WO (1) WO2005027839A2 (is)
ZA (1) ZA200601973B (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
MXPA05008649A (es) * 2003-02-14 2005-11-23 Combinatorx Inc Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
CA2546347A1 (en) 2003-11-21 2005-06-09 Combinatorx, Incorporated Methods and reagents for the treatment of inflammatory disorders
WO2006058022A1 (en) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
JP4954085B2 (ja) 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
PL1719507T3 (pl) 2005-04-13 2010-12-31 Cipher Pharmaceuticals Inc Agoniści receptora beta2-adrenergicznego do leczenia chorób tkanki łącznej skóry
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
WO2007026151A1 (en) * 2005-09-01 2007-03-08 Biolipox Ab Antihistamine- and corticosteroid- containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders
EP2218442A1 (en) * 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US20070179121A1 (en) * 2006-02-02 2007-08-02 Plott R T Method of treating pediatric patients with corticosteroids
KR20080100484A (ko) * 2006-03-07 2008-11-18 버텍스 파마슈티칼스 인코포레이티드 류마티스관절염 치료용 ｖｘ-702의 용도
CA2654498A1 (en) 2006-06-06 2007-12-21 Avigen, Inc. Substituted pyrazolo[1,5-.alpha.]pyridine compounds and their methods of use
WO2008063563A2 (en) * 2006-11-16 2008-05-29 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mtor inhibitors
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
AR066016A1 (es) * 2007-04-11 2009-07-15 Alcon Res Ltd Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica
US7536799B2 (en) * 2007-06-07 2009-05-26 Keson Industries Chalk line apparatus with strategically located chalk fill opening
AU2008302295B2 (en) * 2007-09-18 2013-11-28 Stanford University Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
US8940730B2 (en) 2007-09-18 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010048264A2 (en) * 2008-10-23 2010-04-29 Combinatorx, Incorporated Methods and compositions for the treatment of immunoinflammatory disorders
WO2010107739A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
EA016240B1 (ru) * 2009-10-13 2012-03-30 Федеральное Государственное Учреждение "Государственный Научный Центр Дерматовенерологии Федерального Агентства По Высокотехнологичной Медицинской Помощи" Способ прогнозирования эффективности лечения больных псориазом инфликсимабом
GB201121812D0 (en) 2011-12-07 2012-02-01 Teva Branded Pharmaceutical Prod R & D Inc NAsal formulation
PL2705847T3 (pl) * 2012-09-05 2015-02-27 Psoriasis Creams Sweden Ab Kompozycja do leczenia łuszczycy
CN103830208A (zh) * 2012-11-26 2014-06-04 天津金耀集团有限公司 含有h1受体拮抗剂的吸入制剂
CN103830731A (zh) * 2012-11-26 2014-06-04 天津金耀集团有限公司 糖皮质激素与h1受体拮抗剂的复方吸入组合物
CN103830728A (zh) * 2012-11-26 2014-06-04 天津金耀集团有限公司 环索奈德与h1受体拮抗剂的复方吸入药物
CN103830730A (zh) * 2012-11-26 2014-06-04 天津金耀集团有限公司 布地奈德与h1受体拮抗剂的复方吸入药物
BR102012030828A2 (pt) 2012-12-03 2014-09-16 Ems Sa Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso
US9370527B2 (en) 2012-12-28 2016-06-21 The Regents Of The University Of Michigan Amelioration of intestinal fibrosis and treatment of Crohn's disease
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
CN107106672B (zh) * 2015-01-12 2021-06-22 新加坡科技研究局 用于预防和治疗免疫介导性疾病的针对胞壁酰肽的单克隆抗体
CN104940179B (zh) * 2015-05-29 2017-10-27 中国人民解放军第二军医大学 盐酸苯海拉明在制备治疗实验性自身免疫性脑脊髓炎药物中的应用
JP7068827B2 (ja) 2015-06-30 2022-05-17 アイガー グループ インターナショナル インコーポレイテッド 炎症性状態および癌性状態を治療するための、クロロキン化合物およびクレミゾール化合物の使用
RU2627424C1 (ru) * 2016-11-03 2017-08-08 Лонг Шенг Фарма Лимитед Фармацевтический препарат для лечения ревматологических заболеваний
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
WO2019178516A1 (en) * 2018-03-16 2019-09-19 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
CA3194253A1 (en) * 2020-10-30 2022-05-05 The Board Of Trustees Of The Leland Stanford Junior University Drugs targeting inflammation for the treatment of osteoarthritis and other inflammatory diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3231468A (en) * 1962-07-02 1966-01-25 Merck & Co Inc Dexamethasone-cyproheptadine oral antiflammatory compositions
US3419655A (en) * 1967-03-17 1968-12-31 American Home Prod Treatment of inflammations by administering a cycloleucyl compound
US4444780A (en) * 1982-08-30 1984-04-24 Ortho Pharmaceutical Corporation Method for treating atopic dermatitis
US5166149A (en) * 1989-09-08 1992-11-24 Chemex Pharmaceuticals, Inc. Methotrexate compositions and methods of treatment using same
US5030634A (en) * 1990-03-29 1991-07-09 Krumdieck Carlos L 10-deazaaminopterin: a new arthritis remittive drug
DK0784476T3 (da) * 1994-10-05 2003-03-17 Cari Loder Behandling af multipel sklerose (MS) og andre demyelinisationstilstande under anvendelse af lofepramin i kombination med L-phenylalanin, tyrosin eller tryptophan og eventuelt en vitamin B12-forbindelse
WO1996020712A1 (en) * 1994-12-30 1996-07-11 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
US5736537A (en) * 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
CA2256721A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
IN188720B (is) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
US6423721B1 (en) * 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6492400B1 (en) * 1998-12-18 2002-12-10 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
JP2001510485A (ja) * 1999-03-01 2001-07-31 シェーリング コーポレイション アトピー性皮膚炎、血管性浮腫および他の障害を抗ヒスタミン薬およびグルココルチコイドを用いて処置するための組成物および方法
GB0023220D0 (en) * 2000-09-21 2000-11-01 Arakis Ltd Corticosteroid formulation
US20020006961A1 (en) * 1999-05-14 2002-01-17 Katz Stanley E. Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
ES2284531T3 (es) * 1999-10-08 2007-11-16 Schering Corporation Tratamiento nasal topico usando desloratadina y furoato de mometasona.
CA2405413A1 (en) * 2000-04-07 2001-10-18 Schering Corporation Inhibition of cytokine generation
US6488937B1 (en) * 2000-08-23 2002-12-03 William Smits Allergy treatment method using a rapid immunotherapy protocol
CA2424555A1 (en) * 2000-10-02 2002-04-11 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US6599914B2 (en) * 2001-04-24 2003-07-29 Schering Corporation Inhibition of cytokine generation
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
WO2003020274A1 (en) * 2001-08-30 2003-03-13 Aventis Pharmaceuticals Inc. Treatment of atopic dermatitis
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
MXPA05008649A (es) * 2003-02-14 2005-11-23 Combinatorx Inc Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.

Also Published As

Publication number Publication date
ZA200601973B (en) 2008-08-27
CN101102760A (zh) 2008-01-09
AR047841A1 (es) 2006-03-01
WO2005027839A2 (en) 2005-03-31
EP1670427A4 (en) 2009-01-07
NO20061239L (no) 2006-06-08
KR20060089725A (ko) 2006-08-09
BRPI0414435A (pt) 2006-11-14
RU2006112587A (ru) 2007-10-27
CA2537989A1 (en) 2005-03-31
SG146653A1 (en) 2008-10-30
JP2007516217A (ja) 2007-06-21
WO2005027839A3 (en) 2007-06-28
TW200522932A (en) 2005-07-16
MXPA06002929A (es) 2006-06-14
EP1670427A2 (en) 2006-06-21
IL174185A0 (en) 2006-08-01
AU2004273880A1 (en) 2005-03-31
US20050192261A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
IS8451A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
IS8410A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
IS8497A (is) Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
IS7684A (is) Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
IS7977A (is) Samsetningar og aðferð til samsettra meðferðar
DK3246399T3 (da) Alfavirus-partikler og fremgangsmåder til fremstilling
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
NO20053771L (no) Ringromsfluider og fremgangsmater for plassering av de samme
DK1824475T3 (da) Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
NO20040097L (no) Kombinasjoner for behandling av inflammatoriske forstyrrelser
DK1997809T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
IL179227A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
DK1620551T3 (da) Phospholipase og fremgangsmåde til fremstilling deraf
DK1750713T3 (da) Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner
IS7202A (is) Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum
DK1919290T3 (da) Fremgangsmåder og produkter til behandling af sygdomme
IS8489A (is) Umritunarstillar og aðferðir þeirra
DK1478438T3 (da) Fremgangsmåder og sammensætninger til behandling af astma
EP1611120A4 (en) NEW M THODES FOR THE TREATMENT OF INFLAMMATORY DISEASES
NO20064896L (no) Fremgangsmater for behandling av autoimmune og inflammatoriske sykdommer
DK1589973T4 (da) Formulering og fremgangsmåder til behandling af thrombocytæmi